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Johanna Quist-Nelson, MD; Pamela Parker, MD; Neggin Mokhtari, MD;
Rossana Di Sarno, MD; Gabriele Saccone, MD; Vincenzo Berghella, MDreterm prelabor rupture of mem-OBJECTIVE DATA: Preterm prelabor rupture of membranes occurs in 3% of all preg-
nancies. Neonatal benefit is seen in uninfected women who do not deliver immediately
after preterm prelabor rupture of membranes. The purpose of this study was to evaluate
whether the administration of progestogens in singleton pregnancies prolongs preg-
nancy after preterm prelabor rupture of membranes.
STUDY: Searches were performed in MEDLINE, OVID, Scopus, EMBASE, ClinicalTrials.gov,
and the Cochrane Central Register of Controlled Trials with the use of a combination of
keywords and text words related to “progesterone,” “progestogen,” “prematurity,” and
“preterm premature rupture of membranes” from the inception of the databases until
January 2018. We included all randomized controlled trials of singleton gestations after
preterm prelabor rupture of membranes that were randomized to either progestogens or
control (either placebo or no treatment). Exclusion criteria were trials that included women
who had contraindications to expectant management after preterm prelabor rupture of
membranes (ie, chorioamnionitis, severe preeclampsia, and nonreassuring fetal status)
and trials on multiple gestations. We planned to include all progestogens, including but not
limited to 17-a hydroxyprogesterone caproate, and natural progesterone.
STUDY APPRAISAL AND SYNTHESIS METHODS: The primary outcome was latency from
randomization to delivery. Metaanalysis was performed with the use of the random effects
model of DerSimonian and Laird to produce relative risk with 95% confidence interval.
Analysis was performed for each mode of progestogen administration separately.
RESULTS: Six randomized controlled trials (n¼545 participants) were included. Four of the
included trials assessed the efficacy of 17-a hydroxyprogesterone caproate; 1 trial
assessed rectal progestogen, and 1 trial had 3 arms that compared 17-a hydrox-P branes (PROM), deﬁned as <37
weeks gestational age, occurs in
approximately 3% of pregnancies and
contributes to 40% of preterm births.1
Neonatal outcomes may be improved
with expectant management2 in the
absence of infection to facilitate delivery
at a later gestational age. Yet, many
women with preterm PROM often
deliver within 1 week.3 Antibiotics safely
extend latency and decrease the risks of
maternal and neonatal infection after
preterm PROM.4e6
Progestogen administration has been
studied in different populations7e12
and has been shown to prolong a
pregnancy in speciﬁc populations that
are at risk of prematurity, including
women with a previous spontaneous
preterm birth9,12 and those with a
short cervical length.8,11 These thera-
pies generally are initiated in the sec-
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yprogesterone caproate, rectal progestogen, and placebo. Themean gestational age at time
randomization was 26.9 weeks in the 17-a hydroxyprogesterone caproate group and 27.3
weeks in the control group. 17-a Hydroxyprogesterone caproate administration was not
found to prolong the latency period between randomization and delivery (mean difference,
0.11 days; 95% confidence interval, e3.30 to 3.53). There were no differences in mean
gestational age at delivery, mode of delivery, or maternal or neonatal outcomes between the
2 groups. Similarly, there was no difference in latency for those women who received rectal
progesterone (mean difference, 4.00 days; 95% confidence interval, e0.72 to 8.72).
CONCLUSION: Progestogen administration does not prolong pregnancy in singleton
gestations with preterm prelabor rupture of membranes.
Key words: 17-a hydroxyprogesterone caproate, latency, preterm prelabor rupture of
membranes, progesterone, progestogens, PROMbirth is identiﬁed by history or on ul-
trasound examination.
The underlying mechanisms of
how progesterone prolongs pregnancy,
although not completely understood,MONTH 2018are thought to have to do with
reduction in uterine contractility,13
antimicrobial protein up-regulation,14
immunosuppression, and inﬂammatory
inhibition.15 Speciﬁc to preterm PROM,American Journal of Obstetrics& Gynecology 1
AJOG at a Glance
Why was this study conducted?
The purpose of this study was to investigate whether progestogen administration
after preterm prelabor rupture of membranes (PROM) increases latency of
pregnancy.
Key ﬁndings
Progestogen administration did not prolong pregnancy in singleton gestations
with preterm PROM.
What does this add to what is known?
This study clariﬁes the evidence that progestogen administration should not be
commenced once a patient has experienced preterm PROM.
Systematic Review ajog.orgprogesterone has been shown to
inhibit the tumor necrosis factor and
thrombin-induced mechanisms of mem-
brane weakening.16 Women with preterm
PROM also have been shown to have
lower levels of progesterone receptor
membrane component 1, which is a pro-
tein that is mediated by progesterone to
stabilize the membrane.17 Although pro-
gestogens generally are initiated between
16 and 20 weeks gestation, initiation of
progestogens up to 27 weeks18 is associ-
ated with a decrease in the risk of preterm
birth. Given this beneﬁt in the late second
trimester and the mechanisms of preg-
nancy prolongation in women with a risk
of preterm birth, it is reasonable to suspect
that the administration of progestogens
would result in prolonging pregnancy after
preterm PROM.
The aim of this systematic review and
metaanalysis of randomized controlled
trials was to evaluate the therapeutic
beneﬁt in prolonging pregnancy by the
administration of progesterone therapy in
singleton gestations after preterm PROM.
Materials and methods
Search strategy
The research protocol was designed a
priori, deﬁning methods for searching
the literature, including and examining
articles, and extracting and analyzing
data. Searches were performed in MED-
LINE, OVID, Scopus, ClinicalTrials.gov,
and the Cochrane Central Register of
Controlled Trials with the use of a com-
bination of keywords and text words2 American Journal of Obstetrics& Gynecology Mrelated to “progesterone,” “prematurity,”
“progestogens,” “membrane rupture,”
“17 hydroxyprogesterone,” “vaginal pro-
gesterone,” “tocolysis,” and “preterm
premature rupture or membranes” from
inception of each database until March
2018 (Supplement 1). To locate addi-
tional publications, we reviewed bibliog-
raphies of identiﬁed studies and reviews
articles. No restrictions for language or
geographic location were applied.
Study selection
We included all randomized controlled
trials of singleton gestations after pre-
term PROM that were randomized to
progestogen vs control (either placebo or
no treatment). All published random-
ized controlled trials on any type of
progestogens after the diagnosis of pre-
term PROMat<37 weeks gestationwere
reviewed carefully. Exclusion criteria
included women with short cervix,
quasi-randomized trials (ie, trials in
which allocationwas done on the basis of
a pseudo-random sequence [eg, odd/
even hospital number or date of birth,
alternation]) and trials that included
women who had contraindications to
expectant management after preterm
PROM (ie, chorioamnionitis, severe
preeclampsia, nonreassuring fetal sta-
tus). Trials in women with multiple ges-
tations were also excluded. We planned to
include trials that evaluated any type of
progestogens, including synthetic pro-
gestogens (eg, 17-a hydroxyprogesterone
caproate [17-OHPC]), as well as naturalONTH 2018progesterone. Any route of administration
(eg, oral, intramuscular, rectal, vaginal)
was included.
Before data extraction, the protocol
was registered with PROSPERO (Regis-
tration number: CRD42017068717).
The metaanalysis was reported accord-
ing to the Preferred Reporting Item for
Systematic Reviews and Meta-analyses
(PRISMA) statement.19
Risk of bias
The risk of bias in each included study
was assessed by 2 authors (J.Q-N. and
P.P.) who used the criteria outlined in the
Cochrane Handbook for Systematic
Reviews of Interventions.20 Seven do-
mains related to risk of bias were
assessed in each included trial because
there is evidence that these issues are
associated with biased estimates of
treatment effect: (1) random sequence
generation, (2) allocation concealment,
(3) blinding of participants and
personnel, (4) blinding of outcome
assessment, (5) incomplete outcome
data, (6) selective reporting, and (7)
other bias. Review authors’ judgments
were categorized as “low risk,” “high
risk,” or “unclear risk” of bias.19
Outcomes
Data abstraction was completed by 2
independent investigators (J.Q-N., G.S.).
Each investigator independently
abstracted data from each study and
analyzed data separately.
The primary outcome was time from
randomization until delivery (ie,
latency). This outcome was chosen
because neonatal outcomes after preterm
PROMare correlated with gestational age
at delivery.21 Additionally, increased la-
tency in a patient with preterm PROM
improves survival22 without increasing
incidence of adverse neonatal out-
comes.2,23 The secondary outcomes were
preterm birth at <37, <34, <32, and
<28 weeks gestation, mean gestational
age at delivery, mode of delivery, endo-
metritis, chorioamnionitis, and neonatal
outcomes that included birthweight,
respiratory distress syndrome, intraven-
tricular hemorrhage, necrotizing entero-
colitis, admission to neonatal intensive
FIGURE 1
PRISMA flow chart: Summary of evidence search and selection
Flow diagram of studies identified in the systematic review (Preferred Reporting Item for Systematic Reviews and Meta-analyses template).
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TABLE 1
Characteristics of the included trials
Variable
Study
Total
United States: Briery
et al, 201126
United States: Combs
et al, 201128
United States: Combs
et al, 201524
Iran: Mirzaei and
Moradi, 201527
Iran: Abdali et al,
201729
United States:
Langen et al, 201825
Patients, n (n/N) 69 (33/36) 12 (4/8) 152 (74/78) 171 (57, 17-OHPC;
57, rectal
progesterone; 57
control)
120 (60/60) 21 (10/11) 545
(178,
17-OPHC;
117, rectal;
250, control)
Progestogen
treatment
17-OHPC 17-OHPC 17-OHPC 17-OHPC or rectal
progesterone
Rectal progesterone
suppositories
17-OHPC —
Dose, route,
frequency
250 mg
intramuscularly,
each week
250 mg intramuscularly,
each week
250 mg intramuscularly,
each week
17-OHPC: 250 mg
intramuscularly,
each week; rectal
progesterone: 400
mg daily
Rectal: 400 mg
progesterone
suppository dailya
Not specified
Control Placebo (castor oil) Placebo (castor oil) Placebo (castor oil) No treatment Placebo (castor oil
suppositories)
Vehicle without
progestin component
—
Included range
gestational age at
randomization, wkd
200e300 230e316 230e306 240e340 260 e 320 240e320 —
Inclusion criteria Singleton, vertex,
diagnosis of preterm
PROM
Singleton, >18 years old,
diagnosis of preterm PROM
Singleton, mother
18 years, spontaneous
preterm PROM
Singleton, live,
healthy fetus,
preterm PROM
Singleton, preterm
PROM, desire of
mother to participate
in trial
Singleton, 18
years, confirmed
preterm PROM
Exclusion criteria Intrauterine growth
restriction <5
percentile, suspected
placental abruption,
confirmed placenta
previa (if already
taking 17-OHPC),
chorioamnionitis,
NRFHT, severe
medical or obstetric
disease (SCD with
crisis, IDDM, severe
preeclampsia)
Active preterm labor,
suspected intraamniotic
infection, NRFHT, cervical
dilation 4 cm, fetal death,
preeclampsia, active uterine
bleeding, documented
fetal lung maturity, known
fetal abnormalities (major
congenital malformation,
viral infection, hydrops),
allergy to 17-OHPC or castor
oil, medical conditions that
might adversely interact with
17-OHPC, bmedical conditions
treated with systemic steroid,
cervical cerclage present
at the time of PROM
Active preterm labor, suspected
intraamniotic infection of
inflammation, NRFHT,
intrauterine fetal death,
preeclampsia, active uterine
bleeding, documented fetal
lung maturity, other conditions
that required delivery, fetal
malformations of vital organs
likely to require surgical
repair, fetal viral infection,
hydrops, cerclage present at
time of preterm PROM,
medical conditions treated
with systemic steroids,
contraindications to 17-OHPCc
Fetal anomaly,
multiple gestations,
chorioamnionitis,
NRFHT, placenta
abruption, placenta
previa, intrauterine
growth restriction,
gestational
diabetes mellitus,
preeclampsia,
severe
preeclampsia
Fetal anomalies,d
multiple gestation,
preeclampsia,
chronic
hypertension,
diabetes mellitus,
gestational diabetes
mellitus, abruption,
cord prolapse, active
labor,
chorioamnionitis,
patients presenting
>36 hours after
preterm PROM
Active infection,
placental abruption,
intrauterine fetal
death, major
congenital
malformation, allergy
to progestogen,
those using
progesterone at time
of preterm PROM
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TABLE 1
Characteristics of the included trials (continued)
Variable
Study
Total
United States: Briery
et al, 201126
United States: Combs
et al, 201128
United States: Combs
et al, 201524
Iran: Mirzaei and
Moradi, 201527
Iran: Abdali et al,
201729
United States:
Langen et al, 201825
Included patients
already on vaginal
progesterone or
17-OHPC at time of
preterm PROM
No NR Yese NR NR No
Type of latency
antibiotics
administered
48 hr: Ampicillin
intravenously,
erythromycin
intravenously;
5 days: amoxicillin
orally, erythromycin
orallyf
Varied by hospital siteg Varied by hospital siteg 48 hr: Ampicillin
intravenously;
5 days: amoxicillin
orally, erythromycin
orallyh
48 hr: ampicillin IV
5 days: amoxicillin
orallyi
NR —
Tocolysis Not used Permitted for first 48 hours
at discretion of attending
physician
Permitted for first 48 hr
at discretion of attending
physician
NR Not used Permitted for first 48
hours at discretion of
attending physician
Steroid
administered
Betamethasone Betamethasone or
dexamethasone
Betamethasone Betamethasone Betamethasone Betamethasone
Magnesium sulfate
for neuroprotection
NR NR Used per each hospital
protocol
NR Not giveni Administered if
delivery was believed
to be imminent, at
discretion of treating
physician
Primary outcomes Time from
randomization to
delivery
Continuation of pregnancy
until 340 weeks or until
documented fetal lung
maturity from 320e336
Continuation of pregnancy
until 340 weeks or until
documented fetal lung
maturity from 320e336
NR NR Achievement of 34
weeks gestation
—
Data are presented as total number (progesterone/control) as number (percentage) or as mean  standard deviation.
17-OHPC, 17-a hydroxyprogesterone caproate; IDDM, insulin-dependant diabetes mellitus; NR, not reported; NRFHT, non-reassuring fetal heart tracing; PROM, prelabor rupture of membranes; SCD, sickle cell disease IDDM¼ insulin-dependant diabetes mellitus.
a Cyclogest 400 mg (L.D. Collins and Co, LTD, Middlesex, UK); b includes asthma on medications, renal insufficiency, seizure disorder, ischemic heart disease, cholecystitis, impaired liver function, or history of venous thromboembolism, breast cancer, or depression
that requires hospitalization; c Includes allergy to drug or vehicle, current or past hormone-sensitive cancer, undiagnosed vaginal bleeding, cholestatic jaundice of pregnancy, active liver disease, uncontrolled hypertension; d Fetal anomalies include genetic testing,
structural abnormalities discovered with sonography or trisomy screening test; e Study patients on vaginal progesterone before PROM were recommended to have it discontinued; a patient receiving 17-OHPC was eligible, if willing, to stop previous treatment and be
assigned randomly for the trial; f Study followed Eunice Kennedy Shriver National Institute of Child Health and Human Development protocol; g All hospital sites had a “usual” antibiotic regimen similar to that of Mercer et al5; h Doses of antibiotics: 48 hours of
intravenous ampicillin, 5 days of both amoxicillin 500 mg orally every 8 hours, erythromycin 400 mg orally every 6 hours; i Information obtained in communication with principle investigator.
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6 American Journal of Obstetrics& Gynecology MONTH 2018care unit, neonatal sepsis, and neonatal
death, which was deﬁned as death of a
liveborn baby within the ﬁrst 28 days of
life. Outcomes were assessed separately
by type of progestogen and route of
administration.
Statistical analysis
The data analysis was completed inde-
pendently by authors (J.Q-N., G.S.) with
the use of Review Manager (version 5.3;
The Nordic Cochrane Centre, Cochrane
Collaboration, 2014, Copenhagen,
Denmark). The completed analyses were
then compared, and any difference was
resolved with discussion and involve-
ment of a third party (V.B.).
Data from each eligible study were
extracted without modiﬁcation of orig-
inal data. A 22 table was assessed for
the relative risk; for continuous out-
comes, meansstandard deviation were
extracted and imported into Review
Manager.
Metaanalysis was performed with the
use of the random effects model of
DerSimonian and Laird to produce
summary treatment effects in terms of
relative risk or mean difference (MD)
with 95% conﬁdence interval (CI).
Heterogeneity was measured using
I-squared (Higgins I2). Potential publi-
cation biases were assessed statistically
with Begg’s and Egger’s tests. A proba-
bility value <.05 was considered statis-
tically signiﬁcant.
Results
Study selection and study
characteristics
Figure 1 shows the ﬂow diagram of
study retrieval in the systematic re-
view. No trials were excluded for
quasi-randomization or other meth-
odologic exclusions. Six trials were
included in this metaanalysis with a
total of 525 participants (Table 1).24-28
Patients were assigned randomly be-
tween 20þ0 and 34þ0 weeks. In 4
trials,24-26,28 the intervention was 17-
OHPC administered weekly. In 1
trial,27 the patients received 17-OHPC
rectal progesterone daily. One addi-
tional trial29 assigned patients
randomly to rectal progestogen daily
compared with placebo.
FIGURE 2
Assessment of risk of bias
Risk of bias graph about each risk of bias item presented as percentages across all included studies.
Quist-Nelson. Progestogens after preterm prelabor rupture of membranes. Am J Obstet Gynecol 2018.
ajog.org Systematic ReviewIn 5 trials,24-26,28,29 the patients
received placebo as control. One trial
included women who were already
receiving progesterone therapy beforeFIGURE 3
Assessment of risk of bias
Summary of the risk of bias for each trial: the
plus sign indicates low risk of bias; the minus
sign indicates high risk of bias; the question
mark indicates unclear risk of bias.
Quist-Nelson. Progestogens after preterm prelabor rupture of
membranes. Am J Obstet Gynecol 2018.preterm PROM, but the proportion of
patients already on progesterone was
small (Table 2). The experimental and
control groups were similar in terms of
maternal demographics (Table 2).
All trials administered steroids for
fetal maturity, and 5 of the studies
noted latency antibiotic use,24-26,28,29
although not all studies detailed their
antibiotic regimen (Table 1). The mean
gestational age at time randomization
was 26.9 weeks in the 17-OHPC group
and 27.3 weeks in the control group.
The risk of bias of the included trials
that examined 17-OHPC was judged to
be low overall. The risk of bias for the 2
trials that examined rectal progesterone
was judged as high.27,29 Four of the 6
trials had low risk of bias in random
sequence generation and allocation
concealment (Figures 2 and 3). Statis-
tical heterogeneity within the studies
was moderate with I2¼36% for the
primary outcome.
Synthesis of results
There was no difference in the primary
outcome (Table 3; Figure 4), which was
latency from the time from randomi-
zation to delivery for those patients who
received 17-OHPC (MD, 0.11 days; 95%
CI, e3.30 to 3.53). The primary
outcome was not signiﬁcantly altered in
sensitivity analysis that included only
high-quality trials (MD, e1.60 days;
95% CI, e4.66 to 1.46).24-26,28 There
were no signiﬁcant differences seen in
secondary outcomes in the 17-OHPCMONTH 2018analysis, which included gestational
age at delivery, mode of delivery, cho-
rioamnionitis, endometritis, or
neonatal outcomes that included birth-
weight or adverse neonatal outcomes.
The trials did not report on the in-
cidences of preterm birth at the pre-
speciﬁed intervals of <37, <34, <32,
and <28 weeks gestation. For the rectal
progesterone analysis (Supplemental
Tables 1 and 2), there was no differ-
ence in the primary outcome (MD, 4.00
days; 95% CI, e0.72 to 8.72). The
neonatal intensive care unit length of
stay was shorter in the rectal progester-
one group (MD, e3.70 days; 95% CI,
e4.25 to e3.15), and the birthweight
was higher (MD, 121.27 grams; 95% CI,
96.28e146.25).
Comment
Main ﬁndings
When compared with placebo or no
treatment, progestogens (17-OHPC and
rectal progestin) did not alter the latency
period from randomization to delivery
in singleton gestations with preterm
PROM. Additionally, there was no dif-
ference seen in gestational age at delivery
or in mode of delivery between groups.
No signiﬁcant differences were noted in
maternal or neonatal outcomes. The
differences seen in the rectal progester-
one analysis are to be interpreted with
caution because these trials were judged
to be high risk of bias. The quality of
included trials that examined 17-OHPC
was generally high.
Strengths and limitations
This is the ﬁrst metaanalysis, to our
knowledge, to examine progestogen
administration after preterm PROM. It
follows the Preferred Reporting Item for
Systematic Reviews and Metaanalyses
guidelines and includes trials without
restriction to publication date or lan-
guage. The limitations are inherent to
those limitations of a metaanalysis and
the included trials. Two trials had a high
or unclear risk of bias in all areas of
assessment, and 1 author27 did not
respond to our inquiries regarding their
trials. No trials that evaluated the efﬁcacy
of vaginal progesterone in women with
preterm PROM were found in ourAmerican Journal of Obstetrics& Gynecology 7
TABLE 3
Primary and secondary outcomes for 17-a hydroxyprogesterone caproate and control groups
Outcome
Study
Total I2, %
Relative risk or mean
difference (95%
confidence interval)
Briery et al,
201126
Combs et al,
201128
Combs et al,
201524
Mirzaei and
Moradi, 201527
Langen et al,
201825
Latency from randomization
to delivery, d
11.27.3 vs
14.510.0
11.37.2 vs
9.111.0a
17.116.1 vs
17.015.8
15.216.0 vs
11.510.1b
NR 13.7 vs 13.0 36 0.11 (e3.30e 3.53)
Gestational age at delivery,
wk
27.36.9 vs
29.52.5
304 vs
283
29.22.7 vs
29.52.7
32.22.7 vs
30.9 5.2
NR 29.7 vs 29.5 57 0.02 (e1.40e 1.44)
Spontaneous vaginal
delivery, n/N (%)
24/33 (72.7) vs
24/36 (66.7)
1/4 (25) vs
3/8 (37.5)
29/73 (39.7) vs
43/77 (55.8)
35/57 (61.4) vs
32/57 (56.1)
NR 89/167 (53.3) vs
102/178 (57.3)
34 0.95 (0.75e1.22)
Cesarean delivery, n/N (%) 9/33 (27.3) vs
12/36 (33.3)
3/4 (75) vs
5/8 (62.5)
44/73 (60.3) vs
34/77 (44.2)
22/57 (38.6) vs
25/57 (43.9)
NR 78/167 (46.7) vs
76/178 (42.7)
14 1.12 (0.86e1.45)
Chorioamnionitis, n/N (%) 4/33 (12.1) vs
8/36 (22.2)
1/4 (25) vs
1/8 (12.5)
12/73 (16.4) vs
17/77 (22.1)
15/57 (26.3) vs
13/57 (22.5)
6/10 (60) vs
2/11 (18.2)
38/177 (21.5) vs
41/189 (21.7)
26 1.02 (0.61e 1.69)
Endometritis, n/N (%) NR NR 4/73 (5.5) vs
3/77 (3.9)
NR 3/10 (30) vs
2/11 (18.2)
7/83 (8.4) vs
5/88 (5.7)
0 1.51 (0.52e4.42)
Birthweight, g 1216512 vs
1396446
1328547 vs
1288525
1352501 vs
1405470
198575.8 vs
179373.9
NR 1470.2 vs
1470.5
83 9.12 (e207.89e 226.13)
Respiratory distress
syndrome, n/N (%)
22/33 (66.7) vs
28/36 (77.8)
3/4 (75) vs
7/8 (87.5)
44/73 (60.3) vs
46/77 (59.7)
NR 7/10 (70) vs
10/11 (90.9)
76/120 (63.3) vs
91/132 (68.9)
0 0.91 (0.76e 1.08)
Intraventricular hemorrhage
(grade 3 or 4), n/N (%)
NR 2/4 (50) vs
0/8 (0)
1/73 (1.4) vs
1/77 (1.3)
NR 1/10 (10) vs
2/11 (18.2)
4/87 (4.6) vs
3/96 (3.1)
17 1.48 (0.29e 7.55)
Periventricular
leukomalacia, n/N (%)
NR 0/4 (0) vs
0/8 (0)
1/73 (1.4) vs
2/77 (2.6)
NR NR 1/77 (1.3) vs
2/85 (2.4)
NA 0.53 (0.05e 5.69)
Neonatal sepsis, n/N (%) 6/33 (18.2) vs
6/36 (16.7)
0/4 (0) vs
0/8 (0)
3/73 (4.1) vs
1/77 (1.3)
14/57 (24.6) vs
15/57 (26.3)
4/10 (40.0) vs
1/11 (9.1)
27/177 (15.3) vs
23/189 (12.2)
0 1.14 (0.69e 1.88)
Necrotizing enterocolitis,
n/N (%)
2/33 (6.1) vs
1/36 (2.8)
1/4 (25) vs
0/8 (0)
3/73 (4.1) vs
2/77 (2.6)
NR 2/10 (20) vs
1/11 (9.1)
8/120 (6.7) vs
4/132 (3.0)
0 2.18 (0.72e 6.60)
Neonatal intensive care unit
stay, d
36.4 31.3 vs
37.030.3
4223 vs
5648
NR NR NR 39.2 vs 46.5 0 e2.16 (e15.84e11.53)
Intrauterine fetal death,
n/N (%)
1/33 (3.0) vs
1/36 (2.8)
0/4 (0) vs
0/8 (0)
0/73 (0) vs
0/77 (0)
0/57 (0) vs
3/57 (5.3)
0/10 (0) vs
0/11 (0)
1/177 (0.6) vs
4/189 (2.1)
3 0.42 (0.06e 3.23)
Neonatal death, n/N (%) 3/33 (9.1) vs
2/36 (5.6)
1/4 (25) vs
1/8 (12.5)
3/73 (4.1) vs
2/77 (2.6)
7/57 (12.3) vs
5/57 (8.8)
1/10 (10) vs
0/11 (0)
15/177 (8.5) vs
10/189 (5.3)
0 1.60 (0.76e 3.40)
Data are presented as number of 17-a hydroxyprogesterone caproate/control (percent) as number (percentage) or as mean  standard deviation.
NA, not applicable; NR, not reported.
a Latency originally reported in weeks; data was recalculated from published data; b Variable not specified if time was from rupture until delivery or time from randomization to delivery.
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FIGURE 4
Forest plot for primary outcome
Latency from randomization to delivery after preterm prelabor rupture of membranes.
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ajog.org Systematic Reviewsystematic review. Additionally, the de-
tails of magnesium administration,
which could contribute to confounding
for secondary outcomes, were not re-
ported in all trials.
Because antibiotics previously have
demonstrated beneﬁt to prolonging
latency after preterm PROM,4,5 the
varying antibiotic regimens could
contribute to confounding from the
effect of the progestogens. For example,
1 trial that showed an improved latency
with progestogen administration did not
comment on antibiotic use. Notably, the
trials that were judged of high quality all
used clinically comparable antibiotic
regimens (Table 1); when an analysis was
performed with the use of only these
trials, the primary outcome remained
nonsigniﬁcant.
Comparison with existing literature
and implication
Our results reﬂect the results of each of
the included individual studies that was
judged to be of low risk of bias,
because they did not ﬁnd a difference
in pregnancy latency after preterm
PROM when 17-OHPC was adminis-
tered. Our metaanalysis reﬂects the
results of these trials for both our
primary and secondary outcomes. Two
trials did note a longer latency for pa-
tients who received progestogens. Both
these trials were judged to be high risk
of bias. One trial obtained these results
by combining 17-OHPC and rectal
progestin groups compared with con-
trol group. Our metaanalysis, however,
analyzed 17-OHPC separately fromrectal progesterone, and showed no
signiﬁcant beneﬁt in the latency
period.
Preterm PROM is a frequently
encountered obstetric diagnosis, with
improved neonatal outcomes when an
uninfected mother is able to continue
her pregnancy for a longer duration to
reach a more advanced gestational
age.2,21,22 Thus, data regarding how to
safely prolong pregnancy is pertinent for
appropriate treatment of this popula-
tion. The results of our metaanalysis
suggest that progestogen administration
does not alter the course of a patient
once she has experienced preterm
PROM. These results should encourage
continued research into other
interventions that could beneﬁt this
population. Our data also suggest that
progestogens have different efﬁcacy in
different populations.7e11
In summary, the use of progestogens
after preterm PROM does not prolong
pregnancy compared with placebo or no
treatment. -REFERENCES
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Search strategy used with PubMed
(PPROM OR (preterm premature
rupture of membranes) OR PROM OR
(premature rupture of membranes) ORSUPPLEMENTAL TABLE 1
Demographics at time of randomizat
Demographic
Maternal age, y
Maternal weight, lb
Mean gestational age at membrane rupture, wk
Mean gestational age at randomization, wk
Nulliparous participants
Previous preterm birth
Participants on progesterone at time of preterm
Data are given as the mean standard deviation in the rectal p
NR, not reported; PROM, prelabor rupture of membranes.
a Gestational age reported in days.
Quist-Nelson. Progestogens after preterm prelabor rupture o(premature rupture of membrane) OR
(membrane rupture) OR (prematurity))
AND (progesterone OR (17-
hydroxyprogesterone caproate) OR
(progestogen)) AND ((randomized
controlled trial[pt] OR controlledion for rectal progesterone compared w
Study
Mirzaei F, Moradi
P, 201527 (n[171)
NR
NR
29.752.79 vs 30.242.47
NR
NR
NR
PROM NR
rogesterone vs the control group or as data presented as the number
f membranes. Am J Obstet Gynecol 2018.
MONTH 2018 Ameclinical trial[pt] OR randomized[tiab]
OR placebo[tiab] OR drug therapy[sh]
OR randomly[tiab] OR trial[tiab] OR
groups[tiab]) NOT (animals[mh] NOT
humans[mh]))ith control subjects
Abdali et al, 201729
(n[120)
29.565.66 vs 29.885.57
NR
203.0513.22 vs 203.3215.48a
1/60 vs 0/60
NR
NR
NR
s in the rectal progesterone group/control group.
rican Journal of Obstetrics& Gynecology 10.e1
SUPPLEMENTAL TABLE 2
Primary and secondary outcomes for rectal progesterone compared with control
Variable
Study
I2, %
Relative risk or
mean difference (95%
confidence interval)
Mirzaei F, Moradi P, 201527
(n[171) Abdali et al, 201729 (n[120)
Latency from randomization to
delivery, d
15.515.1 vs 11.510.1a NRb — 4.00 (e0.72e8.72)
Gestational age at delivery, wk 32.12.3 vs 30.9 5.2 212.1012.29 vs 209.6711.96c — 1.20 (e0.28e2.68)d
Spontaneous vaginal delivery,
n/N (%)
33/57 (57.9) vs 32/57 (56.1) 34/60 (56.7) vs 25/60 (41.7) 19 1.16 (0.89e1.53)
Cesarean delivery, n/N (%) 24/57 (42.1) vs 25/57 (43.9) NR — 1.08 (0.72e1.61)
Chorioamnionitis, n/N (%) 14/57 (24.6) vs 13/57 (22.5) 0/60 (0) vs 0/60 (0) — 1.10 (0.46e 2.61)
Endometritis NR NR —
Birthweight, g 191364.2 vs 179373.9 1609.9417.3 vs 1452.0342.4 0 121.27 (96.28e146.25)
Respiratory distress syndrome,
n/N (%)
NR 53/60 (88.3) vs 48/60 (80.0) — 1.89 (0.69e5.20)
Intraventricular hemorrhage
(grade 3 or 4)
NR NR —
Periventricular leukomalacia NR NR —
Neonatal sepsis, n/N (%) 15/57 (26.3) vs 15/57 (26.3) 0/60 (0) vs 1/60 (1.75) 0 0.96 (0.53e1.76)
Necrotizing enterocolitis, n/N (%) NR 0/60 (0) vs 0/60 (0) —
Neonatal intensive care unit stay, d NR 10.531.10 vs 14.231.89 — e3.70 (e4.25e e3.15)
Intrauterine fetal death, n/N (%) 2/57 (3.5) vs 3/57 (5.3) NR — 0.67 (0.12e3.84)
Neonatal death (within 28 days),
n/N (%)
4/57 (5.0) vs 5/57 (8.8) NR — 0.80 (0.23e2.83)
Data are presented as number in rectal progesterone/control groups (percent) as number (percentage) or as mean  standard deviation.
NR, not reported.
a Variable not specified whether date are time from rupture until delivery or time from randomization to delivery; b Latency reported as mean without standard deviation; c Reported in days, data per
report in communication with principle investigator; d Calculated from Mirzaei and Moradi only because the gestational age for Abdali et al was provided in days.
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